Highlights from the blog
Critics say pharma's skimpy research spending is out of whack with its outsized revenues. The data say otherwise.
Reciprocal approval sounds appealing, but new data suggest its potential clinical benefits may be overstated.
New data on drug ramp rates could increase the financial attractiveness of “pioneer” projects.
We found 31 Phase 2 assets that could be deal targets if private biotechs can't access public capital - but only for pharmas that can stomach a little risk.
A timely test case for the math behind "value-based pricing".
There are plenty of ways to win in diagnostics - Theranos just needs to pick one.